Carve-Out Under Pressure: Why EyeCare Partners Abandoned the Roll-Up Model

ST. LOUIS, MO – September 28, 2026 – In the halcyon days of zero-interest-rate policy, the healthcare "roll-up" was considered a foolproof private equity playbook. Buy a platform, bolt on hundreds of regional practices, arbitrage the valuation multiples, and sell at a premium. But as we navigate the complex and unforgiving 2026 investment landscape, the bill for that aggressive leverage has come due. Today's announcement that EyeCare Partners LLC (ECP) is selling its entire optometry business to MyEyeDr. is more than just a corporate divestiture—it is a glaring symbol of the great unbundling of the unified healthcare consolidation model.

The St. Louis-based company, which operates a massive national network of over 300 ophthalmologists and 700 optometrists, confirmed it has entered into a definitive agreement to offload its optometry division. The transaction, expected to close in the fourth quarter of 2026 pending regulatory antitrust approvals, will see ECP pivot its business model entirely toward high-acuity ophthalmology and ambulatory surgical centers (ASCs). Concurrently, the company launched an exchange offer for certain outstanding term loans, supported by an ad hoc group holding approximately 81% of its second-out term loan.

"We went to great lengths to find the ideal partner for our optometry business, with a commitment to clinical excellence and high-quality patient care being a key requirement. MyEyeDr. will build on the strength of the business and support its next phase of growth," said Chris Throckmorton, Chief Executive Officer of EyeCare Partners, in the official press release.

Yet, looking beyond the carefully crafted corporate optimism, the underlying catalyst for this transaction is a textbook case of distressed debt restructuring.

The 2027 Debt Wall and the PIK Cliff

To understand "the why behind the buy"—or in this case, the sell—investors must examine the capitalization table. EyeCare Partners accumulated a mountain of debt during its aggressive 2020 to 2022 acquisition spree, following its late 2019 buyout by Swiss private equity giant Partners Group at a valuation exceeding $2.2 billion.

By early 2024, facing macroeconomic headwinds, severe clinician wage inflation, and soaring benchmark interest rates, the company was forced into an out-of-court liability management transaction. That restructuring exchanged approximately $2.1 billion of legacy loans and introduced a new superpriority tranche to bolster liquidity. However, it only purchased temporary runway via a Payment-in-Kind (PIK) interest toggle on its massive $1.495 billion second-out superpriority term loan.

The clock was ticking. In December 2025, S&P Global Ratings downgraded the company to CCC- with a negative outlook, citing persistent free operating cash flow deficits and an impending crisis. The partial PIK option was slated to expire in January 2027, which would have triggered a cash interest burden surge of nearly 45%. The operating cash flows simply could not support that jump.

Faced with this impending "PIK cliff," the board was forced to act. The divestiture of the optometry business is estimated by market analysts to command a transaction value in the range of $650 million to $900 million, based on recalibrated EBITDA multiples of 10x to 13x. A significant portion of these net proceeds is earmarked directly for paying down the senior debt at par or through discounted buybacks, while remaining debt in the participating tranches will be rolled into extended 2029-2030 maturities.

Unbundling the Clinical Continuum

The financial engineering is only half the story; the strategic retreat is equally compelling. The foundational thesis of the organization's consolidation model was vertical integration across the eye care continuum. The strategy was elegantly simple on paper: optometrists perform routine exams and prescribe glasses, acting as the top of the funnel. When patients develop cataracts, glaucoma, or macular degeneration, those optometrists refer them internally to the company's ophthalmologists. Surgeries are then channeled into company-owned ASCs, capturing facility fees and surgical professional fees under one corporate umbrella.

So why did the one-stop-shop model stumble? The synergy assumptions broke down under the weight of market realities. While the referral pipeline was theoretically sound, the unit economics of the two disciplines are vastly different.

Ambulatory Surgical Centers deliver significantly higher EBITDA margins—typically between 25% and 35%—driven by commercial medical insurance and Medicare Part B reimbursements for high-value procedures. Conversely, retail optometry operates on thinner margins of 12% to 18%, heavily burdened by retail lease costs, expensive frame inventory, and the steep discounts demanded by managed vision care networks.

By severing the optometry arm, the company is retreating to its most profitable core. It retains over 300 ophthalmologists, specialized clinical centers, and more than 30 ASCs across key regional hubs. This insulates the remaining platform from commercial optical insurance pressures and retail overhead, albeit at the cost of losing a captive patient referral pipeline.

MyEyeDr. Doubles Down on Retail Scale

On the other side of the transaction sits MyEyeDr., operated by Capital Vision Services and backed by Goldman Sachs Asset Management and Charlesbank Capital Partners. While the seller is retreating from retail, the buyer is doubling down.

Prior to this deal, MyEyeDr. operated over 840 locations. Absorbing the 300-plus optometry offices—including prominent regional anchor brands like Clarkson Eyecare in the Midwest, Nationwide Vision in the Southwest, and EyeCare Associates in the Southeast—expands its footprint to over 1,200 retail and clinic locations. This cements its position as the undisputed largest pure-play optometry provider in North America.

For MyEyeDr., the acquisition is a pure scale play. By focusing exclusively on primary vision care, clinical technology, and eyewear dispensing, the platform can standardize practice management and leverage its massive size to negotiate better reimbursement rates with vision insurance payers.

However, the transaction will not be without regulatory hurdles. The Federal Trade Commission and state Attorneys General have increasingly scrutinized private equity roll-ups in localized healthcare markets. Antitrust reviews will likely center on metropolitan areas where both entities maintain overlapping retail presences, such as St. Louis and Phoenix, to ensure the consolidation does not negatively impact consumer optical pricing or insurance network access.

The New Era of Healthcare Investment

This landmark divestiture serves as a bellwether for the broader 2026 investment landscape. Much like the broader market's pivot away from growth-at-all-costs tech and the ongoing rotation into value stocks amid "AI fatigue," the era of the bloated, heavily leveraged healthcare platform is giving way to a period of strategic retrenchment. Private equity sponsors are realizing that mashing together high-margin surgical specialties with low-margin retail operations creates organizational friction that becomes unsustainable when debt becomes expensive.

As we look ahead, the market is aggressively repricing these assets. Investors are shifting their focus away from top-line revenue aggregation and toward pure-play operational efficiency. The companies that will thrive in this new high-cost-of-capital environment are those that ruthlessly optimize their core competencies rather than trying to own the entire patient journey. For EyeCare Partners, survival meant shrinking to grow stronger, proving that in today's market, focused profitability always wins over debt-fueled scale.